Jazz Pharmaceuticals plc (JAZZ) Earnings History
Profitable21 years of earnings data (2005–2025) · Positive TTM net income
Loading earnings history...
Jazz Pharmaceuticals plc (JAZZ) Earnings Overview
As of November 8, 2026, Jazz Pharmaceuticals plc (JAZZ) reported trailing twelve-month net income of $206M, reflecting -167.5% year-over-year growth. The company earned $3.18 per diluted share over the past four quarters, with a net profit margin of -8.3%.
Looking at the long-term picture, JAZZ's historical earnings data spans multiple years. The company achieved its highest annual net income of $560M in fiscal 2024.
Jazz Pharmaceuticals plc maintains positive profitability with a gross margin of 88.2%, operating margin of 5.3%, and net margin of -8.3%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including SUPN ($72M net income, -5.4% margin), PCRX ($15M net income, 1.0% margin), INVA ($357M net income, 63.8% margin), JAZZ has room to improve margins relative to the peer group. Compare JAZZ vs SUPN →
JAZZ Earnings vs Peers
Earnings metrics vs comparable public companies
JAZZ Historical Earnings Data (2005–2025)
21 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$356M | -163.6% | $224M | $-5.84 | -8.3% | 5.3% |
| 2024 | $560M | +35.0% | $717M | $8.65 | 13.8% | 17.6% |
| 2023 | $415M | +285.1% | $579M | $6.10 | 10.8% | 15.1% |
| 2022 | -$224M | +31.9% | -$66M | $-3.58 | -6.1% | -1.8% |
| 2021 | -$329M | -237.9% | $170M | $-5.51 | -10.6% | 5.5% |
| 2020 | $239M | -54.4% | $378M | $4.22 | 10.1% | 16.0% |
| 2019 | $523M | +17.1% | $532M | $9.09 | 24.2% | 24.6% |
| 2018 | $447M | -8.4% | $615M | $7.30 | 23.6% | 32.5% |
| 2017 | $488M | +22.9% | $529M | $7.96 | 30.1% | 32.7% |
| 2016 | $397M | +20.4% | $592M | $6.41 | 26.7% | 39.8% |
| 2015 | $330M | +464.4% | $508M | $5.23 | 24.9% | 38.4% |
| 2014 | $58M | -73.0% | $196M | $0.93 | 5.0% | 16.7% |
| 2013 | $216M | -25.0% | $340M | $3.51 | 24.8% | 39.0% |
| 2012 | $289M | +130.9% | $198M | $4.79 | 49.2% | 33.8% |
| 2011 | $125M | +281.3% | $128M | $2.67 | 45.9% | 46.9% |
| 2010 | $33M | +579.5% | $58M | $0.83 | 18.9% | 33.3% |
| 2009 | -$7M | +96.3% | $16M | $-0.23 | -5.3% | 12.4% |
| 2008 | -$184M | -32.8% | -$170M | $-7.19 | -273.0% | -252.3% |
| 2007 | -$139M | -133.7% | -$139M | $-10.04 | -212.6% | -212.5% |
| 2006 | -$59M | +30.3% | -$78M | $-4.41 | -132.4% | -174.0% |
| 2005 | -$85M | - | -$78M | $-6.32 | -397.1% | -365.8% |
Download Data
Export JAZZ earnings history in CSV or JSON format
Free sign-in required to download data
JAZZ Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
21+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
JAZZ — Frequently Asked Questions
Quick answers to the most common questions about buying JAZZ stock.
What is JAZZ earnings per share (EPS)?
JAZZ trailing twelve-month (TTM) diluted EPS is $3.18, reflecting -167.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2005 to 2025 is available in the table on this page.
What is Jazz Pharmaceuticals plc's net income?
Jazz Pharmaceuticals plc (JAZZ) trailing twelve-month net income is $206M as of 2025. Earnings declined -167.5% year-over-year.
Is JAZZ profitable?
Yes, JAZZ is profitable with a TTM net income of $206M and a net profit margin of -8.3%.
What is JAZZ's earnings growth rate?
JAZZ compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2005 to 2025.
What are JAZZ's profit margins?
Jazz Pharmaceuticals plc net profit margin is -8.3%, operating margin is +5.3%, and gross margin is +88.2%. Below-average margins reflect competitive or cost pressures. Return on Equity is -8.5%.
Is JAZZ growing earnings?
JAZZ earnings are declining — EPS fell -167.5% year-over-year. TTM net income dropped to $206M. This contrasts with the 5-year CAGR of N/A.
What was JAZZ's best earnings year?
Jazz Pharmaceuticals plc's highest annual net income on record is $560M, achieved in fiscal year 2024. Earnings history on this page spans 2005 to 2025 and includes all annual and quarterly figures.
What were JAZZ's earnings last quarter?
JAZZ's most recent reported quarter was Q3 2026. Net income was $-483M with diluted EPS of $-7.48. For a full breakdown of all quarters, see the quarterly earnings table on this page.